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A BS TR AC T
BACKGROUND
Cushing’s disease is associated with high morbidity and mortality. Pasireotide, a poten-
tial therapy, has a unique, broad somatostatin-receptor–binding profile, with high 
binding affinity for somatostatin-receptor subtype 5.
METHODS
In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing’s 
disease and a urinary free cortisol level of at least 1.5 times the upper limit of the 
normal range to receive subcutaneous pasireotide at a dose of 600 µg (82 patients) 
or 900 µg (80 patients) twice daily. Patients with urinary free cortisol not exceeding 
2 times the upper limit of the normal range and not exceeding the baseline level at 
month 3 continued to receive their randomly assigned dose; all others received an 
additional 300 µg twice daily. The primary end point was a urinary free cortisol 
level at or below the upper limit of the normal range at month 6 without an in-
creased dose. Open-label treatment continued through month 12.
RESULTS
Twelve of the 82 patients in the 600-µg group and 21 of the 80 patients in the 900-µg 
group met the primary end point. The median urinary free cortisol level decreased by 
approximately 50% by month 2 and remained stable in both groups. A normal urinary 
free cortisol level was achieved more frequently in patients with baseline levels not 
exceeding 5 times the upper limit of the normal range than in patients with higher 
baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, 
and clinical signs and symptoms of Cushing’s disease diminished. Pasireotide was 
associated with hyperglycemia-related adverse events in 118 of 162 patients; other 
adverse events were similar to those associated with other somatostatin analogues. 
Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels in-
creased soon after treatment initiation and then stabilized; treatment with a glu-
cose-lowering medication was initiated in 74 of 162 patients.
CONCLUSIONS
The significant decrease in cortisol levels in patients with Cushing’s disease who re-
ceived pasireotide supports its potential use as a targeted treatment for corticotropin-
secreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov num-
ber, NCT00434148.)
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Cushing’s disease is a rare disorder of chronic hypercortisolism due to a corti-cotropin-secreting pituitary adenoma. The 
disorder is associated with central obesity, osteopo-
rosis, arterial hypertension, insulin resistance, glu-
cose intolerance, diabetes mellitus, dyslipidemia, 
cardiovascular disease, and increased mortality.1-5
Transsphenoidal surgery is the primary therapy 
in most patients, with remission rates of 65 to 
90% when an expert pituitary surgeon operates.6 
However, remission definitions vary, and relapse 
occurs in up to 30% of patients. Second-line op-
tions include repeat pituitary surgery, radiation 
therapy, bilateral adrenalectomy, and medical ther-
apy. However, current medical treatments have not 
been tested in large prospective, randomized trials.
Corticotroph adenomas express somatostatin 
receptors, predominantly somatostatin-receptor 
subtype 5.7 Activation of this subtype inhibits cor-
ticotropin secretion, providing a potential thera-
peutic target for Cushing’s disease.8-10
Pasireotide (SOM230) is a somatostatin ana-
logue that targets four of the five somatostatin 
receptors, with highest affinity for subtype 5.11 
This unique receptor-binding profile and the posi-
tive results in a proof-of-concept study12 provided 
the rationale for the present study.
Me thods
PATIENTS
Eligible patients in this multicenter, phase 3 study 
were adults (≥18 years of age) with confirmed per-
sistent or recurrent Cushing’s disease or newly 
diagnosed disease, if they were not candidates 
for surgery. Cushing’s disease was defined by a 
mean 24-hour urinary free cortisol level of at least 
1.5 times the upper limit of the normal range, 
calculated from four 24-hour samples collected 
within 2 weeks; a morning plasma corticotropin 
level of 5 ng per liter (1.1 nmol per liter) or more; 
and a confirmed pituitary source of Cushing’s 
syndrome. Key exclusion criteria were pituitary 
irradiation within the previous 10 years, compres-
sion of the optic chiasm causing visual-field de-
fects, symptomatic cholelithiasis, and a glycated 
hemoglobin level of more than 8% (for further 
details, see the Supplementary Appendix, available 
with the full text of this article at NEJM.org).
STUDY OVERSIGHT AND SUPPORT
The study was approved by the independent ethics 
committee, research ethics board, or institutional 
review board at each center and complied with the 
Declaration of Helsinki, the Harmonized Tripar-
tite Guideline for Good Clinical Practice from the 
International Conference on Harmonization, and 
local laws. All patients provided written informed 
consent. The study was funded by Novartis Phar-
ma. Financial support for medical editorial assis-
tance was provided by Novartis Pharma.
The study was designed by the academic inves-
tigators and the study sponsor, Novartis Oncology. 
Data were collected by the site investigators with 
the use of Novartis data-management systems and 
were analyzed by the Novartis statistical team. All 
authors contributed to data interpretation and the 
writing, reviewing, and amending of the manu-
script; the first draft was prepared by one of the 
academic authors and a medical writer funded by 
Novartis Pharma. All the authors made the deci-
sion to submit the manuscript for publication and 
vouch for the accuracy and completeness of the 
data and for the fidelity of the study to the proto-
col (available at NEJM.org).
STUDY DESIGN
After screening of 329 patients and appropriate 
washout of cortisol-lowering medications, 162 pa-
tients were randomly assigned to subcutaneous 
pasireotide at a dose of 600 µg (82 patients) or 
900 µg (80 patients) twice daily. Patients with a 
urinary free cortisol level not exceeding 2 times the 
upper limit of the normal range and not exceeding 
the baseline level at month 3 continued to receive 
their randomly assigned dose, in a double-blind 
fashion, through month 6. Study assignments were 
revealed to all other patients at month 3, and the 
doses were increased by 300 µg twice daily. At 
month 6, patients entered an open-label phase that 
lasted through month 12; during this phase, if the 
urinary free cortisol level was above the upper limit 
of the normal range, the dose could be increased by 
300 µg twice daily (maximum, 1200 µg twice dai-
ly) at any time. Throughout the 12-month treatment 
period, if dose adjustment was required because of 
adverse events, the dose could be reduced in steps 
of 300 µg twice daily. After month 12, patients 
could enter an open-label extension of the trial.
END POINTS AND ASSESSMENTS
The primary end point of the study was a normal-
ized urinary free cortisol level. Patients were con-
sidered to have normalized urinary free cortisol if 
the level was at or below the upper limit of the nor-
mal range at month 6 without a prior dose increase.
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Prespecified secondary efficacy end points were 
a urinary free cortisol level at or below the upper 
limit of the normal range at months 3, 6, and 
12, regardless of dose adjustment; partial control 
of hypercortisolism (a urinary free cortisol level 
above the upper limit of the normal range but re-
duced by ≥50% from baseline); levels of plasma 
corticotropin, urinary free cortisol, and serum and 
salivary cortisol over time; changes in clinical 
signs and symptoms; quality of life; and safety.
The urinary free cortisol level, assessed 
monthly for 6 months and every 3 months there-
after, was calculated as the mean value of three or 
four samples, collected within a 14-day period at 
months 3, 6, and 12 and as the mean value in two 
consecutive-day samples at other time points. If 
the measurement at month 6 was missing, the 
most recent available value (on the basis of ≥3 col-
lections) between months 3 and 6 was carried 
forward. Patients for whom valid measurements 
were not available and those who discontinued the 
study medication before month 3 were consid-
ered to have uncontrolled hypercortisolism (see 
the Supplementary Appendix for details of serum 
cortisol and plasma corticotropin collection and 
assay).
Systolic and diastolic blood pressure, body 
weight, body-mass index, and levels of triglycer-
ides and low-density lipoprotein (LDL) cholesterol 
were assessed monthly. At baseline and at months 
6 and 12, a reviewer at each site assessed patients 
for signs of hypercortisolism (facial rubor and su-
praclavicular and dorsal fat pads) by scoring pho-
tographs on a scale from 0 to 3 (with 0 indicating 
Table 1. Baseline Demographic and Clinical Characteristics of the Overall Study Population and Each Dose Group.*
Characteristic
Pasireotide 600 µg 
Twice Daily 
(N = 82)
Pasireotide 900 µg 
Twice Daily 
(N = 80)
Overall 
(N = 162)
Female sex — no. (%) 62 (76) 64 (80) 126 (78)
Age
Mean — yr 41 40 40
Range — yr 18–67 19–71 18–71
≥65 yr — no. (%) 4 (5) 1 (1) 5 (3)
Race or ethnic group — no. (%)†
White 65 (79) 62 (78) 127 (78)
Black 2 (2) 1 (1) 3 (2)
Asian 10 (12) 10 (12) 20 (12)
Native American 2 (2) 2 (2) 4 (2)
Other 3 (4) 4 (5) 7 (4)
Missing data 0 1 (1) 1 (1)
Time since diagnosis — mo
Mean 53.4 54.7 54.0
Range 0.1–341.8 0.1–372.1 0.1–372.1
Previous treatment — no. (%)
Surgery 64 (78) 64 (80) 128 (79)
Medication 36 (44) 42 (52) 78 (48)
Pituitary irradiation 3 (4) 4 (5) 7 (4)
Urinary free cortisol
Baseline measurement — no. of patients (%) 77 (94) 76 (95) 153 (94)
≥3 samples collected — no. of patients (%) 77 (94) 76 (95) 153 (94)
Level — nmol/24 hr
Mean 1156 782 970
Median 730 487 565
Range 220–22,944 195–6123 195–22,944
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no signs, 1 mild hypercortisolism, 2 moderate hy-
percortisolism, and 3 severe hypercortisolism). The 
reviewers were physicians who were experienced 
in treating patients with Cushing’s disease but who 
were not involved in other aspects of the study, had 
no direct contact with the study patients, and were 
unaware of both the study-group assignments and 
the timing of the photographs (whether they were 
taken during or after treatment). Health-related 
quality of life was measured with the use of the 
CushingQoL questionnaire (in which scores range 
from 0 to 100, with higher scores indicating better 
quality of life).13 Tumor volume was assessed by 
magnetic resonance imaging (MRI) at baseline and 
at months 6 and 12 (or at the time of study-drug 
discontinuation in the case of early withdrawal 
from the study) and evaluated by a central reader 
(see the Supplementary Appendix).
At each visit, hematologic and blood biochem-
ical measurements, urinalysis, and electrocardi-
ography were performed, and vital signs and 
physical condition were assessed. Ultrasonography 
of the gallbladder was performed at baseline and 
at months 3, 6, and 12. Adverse events were graded 
according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, ver-
sion 3.0.14
STATISTICAL ANALYSIS
The proportion of patients with a urinary free cor-
tisol level at or below the upper limit of the normal 
range was calculated for the intention-to-treat pop-
ulation at all time points. With a null hypothesis 
that no more than 15% of patients would meet the 
primary end point and an alternative hypothesis 
that 30% would meet the primary end point, we 
calculated that enrollment of 146 patients would 
provide 87% power to show statistical significance 
for each of the two within-group tests. Patients 
were grouped by randomly assigned dose. If the 
lower bound of the 95% confidence interval for a 
dose group was greater than the predetermined 
15%, that group was considered to have met the 
primary end point. Changes in biochemical mea-
sures and signs and symptoms over time were as-
sessed according to the number of patients with 
data that could be evaluated at each time point. 
Safety was assessed up to the data cutoff date. The 
study was not powered to detect statistically sig-
nificant differences between dose groups or chang-
es in secondary end points within dose groups; 
however, post hoc t-tests were performed without 
multiplicity adjustment to assess the statistical 
significance within each study group and in the 
combined group. Secondary end points are sum-
Table 1. (Continued.)
Characteristic
Pasireotide 600 µg 
Twice Daily 
(N = 82)
Pasireotide 900 µg 
Twice Daily 
(N = 80)
Overall 
(N = 162)
Severity of hypercortisolism — no. (%)‡
Mild 12 (15) 14 (18) 26 (16)
Moderate 26 (32) 40 (50) 66 (41)
Severe 28 (34) 13 (16) 41 (25)
Very severe 11 (13) 9 (11) 20 (12)
Missing data 5 (6) 4 (5) 9 (6)
Months of study completed — no. of patients (%)§
3 68 (83) 65 (81) 133 (82)
6 54 (66) 53 (66) 107 (66)
12 39 (48) 39 (49) 78 (48)
* The study was not powered to detect significant differences between dose groups.
† Race or ethnic group was determined by the site investigator and recorded on the case-report forms.
‡ Mild hypercortisolism was defined as an elevated urinary free cortisol level that did not exceed 2 times the upper limit 
of the normal range (ULN) (145 nmol per 24 hours [52.5 μg per 24 hours]), moderate hypercortisolism as a level that was 
more than 2 times to 5 times the ULN, severe hypercortisolism as a level that was more than 5 times to 10 times the ULN, 
and very severe hypercortisolism as a level that was more than 10 times the ULN.
§ In the first 3 months, 29 patients discontinued the study: 13 because of adverse events, 4 because of lack of efficacy,  
9 because of withdrawal of consent, and 3 because of a protocol violation. By month 6, an additional 26 patients had 
discontinued the study: 7 because of adverse events, 15 because of lack of efficacy, and 4 because of withdrawal of 
 consent. By month 12, an additional 29 patients had discontinued the study: 6 because of adverse events, 18 because 
of lack of efficacy, 4 because of withdrawal of consent, and 1 because of a protocol violation.
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marized descriptively. All statistical tests were two-
sided. The statistical analysis plan is included in 
the protocol.
R esult s
STUDY PATIENTS
At baseline, 78% of patients had moderate-to-very-
severe hypercortisolism (Table 1). The proportion 
of patients with a baseline mean urinary free cor-
tisol level that was more than 5 times the upper 
limit of the normal range was higher in the 600-µg 
group than in the 900-µg group (48% vs. 28%). The 
median baseline urinary free cortisol level in the 
600-µg and 900-µg groups was 730 and 487 nmol 
per 24 hours, respectively.
The mean treatment duration was 10.8 months 
(range, 0.03 to 37.8). Seventy-eight patients (48%) 
completed 12 months of treatment (Table 1). 
Although discontinuations occurred throughout 
the study, 71% of patients with fully or partially 
controlled hypercortisolism at month 1 or 2 con-
tinued to receive treatment through month 12, as 
compared with 25% of those with uncontrolled 
hypercortisolism at months 1 and 2.
The mean daily dose of pasireotide in the 
600-µg and 900-µg groups at months 3, 6, and 12 
was 1165 µg and 1701 µg, 1353 µg and 1875 µg, 
and 1569 µg and 1813 µg, respectively. At month 
12, 19 patients were receiving pasireotide at a dose 
of 1200 µg twice daily.
EFFICACY
Urinary Free Cortisol
In the majority of patients, the urinary free cortisol 
level decreased from baseline to month 6 (Fig. 1). 
At month 6, 15% (95% confidence interval [CI], 
7 to 22) of patients in the 600-µg group and 26% 
(95% CI, 17 to 36) of those in the 900-µg group 
had urinary free cortisol levels at or below the up-
per limit of the normal range without a prior dose 
increase. The null hypothesis was rejected in the 
900-µg group (i.e., the lower bound of the 95% 
confidence interval for the response rate in the 
900-µg group was >15%).
At month 3, 16% (95% CI, 8 to 24) of patients 
in the 600-µg group and 28% (95% CI, 18 to 37) 
of those in the 900-µg group had urinary free 
cortisol levels at or below the upper limit of the 
normal range; 45 patients (28%) had their dose 
increased: 29 (35%) in the 600-µg group and 16 
(20%) in the 900-µg group. With the inclusion 
of patients who had an increased dose at month 
3, 16% (95% CI, 8 to 24) of patients in the 600-µg 
group and 29% (95% CI, 19 to 39) of those in the 
900-µg group had normalized urinary free corti-
sol levels at month 6.
At month 12, 13% (95% CI, 6 to 21) of patients 
in the 600-µg group and 25% (95% CI, 16 to 35) 
of those in the 900-µg group had urinary free 
cortisol levels at or below the upper limit of the 
normal range. In 20 of the 36 patients with nor-
malized urinary free cortisol levels at month 6, 
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Figure 1. Absolute Change in Urinary Free Cortisol Levels from Baseline to Month 6.
Urinary free cortisol was available at baseline and at month 6 in a total of 103 patients; 50 patients had a substantial re-
duction (either normalization or ≥50% reduction from baseline) in urinary free cortisol level at month 6. The black 
dashed line represents the upper limit of the normal range (ULN) (145 nmol per 24 hours [52.5 μg per 24 hours]). 
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the levels remained normal at month 12. Patients 
whose dose was reduced to 300 µg twice daily 
(5 patients) or 600 µg twice daily (6 patients) con-
tinued to have normal urinary free cortisol levels. 
Partial control of hypercortisolism was achieved 
in 18% and 13% of patients in the 600-µg and 
900-µg groups at month 6 and in 16% and 3% at 
month 12, respectively. Patients with lower base-
line urinary free cortisol levels (≤5 times the up-
per limit of the normal range) had a higher rate of 
response (Fig. 2).
The reduction in mean urinary free cortisol 
levels was rapid and sustained (Fig. 2, and the 
Supplementary Appendix). Among the 72 patients 
with uncontrolled hypercortisolism at months 
1 and 2, hypercortisolism remained uncontrolled 
in 66 patients (92%) at month 6 and in 64 pa-
tients (89%) at month 12.
Plasma Corticotropin and Serum and Salivary 
Cortisol
Mean plasma corticotropin and serum and salivary 
cortisol levels decreased from baseline to month 
12 in both dose groups. In the overall population, 
the mean percentage change in the morning serum 
cortisol level was −7.4% (95% CI, −13.4 to −1.5) and 
−13.4% (95% CI, −19.7 to −7.0) at months 6 and 
12, respectively. The mean percentage change in 
the midnight salivary cortisol level was −3.7% (95% 
CI, −32.5 to 25.1) and −12.4% (95% CI, −32.5 to 7.6) 
at months 6 and 12, respectively. The mean per-
centage change in the plasma corticotropin level 
was −12.8% (95% CI, −20.1 to −5.4) and −16.9% 
(95% CI, −27.0 to −6.8) at months 6 and 12, re-
spectively.
Signs and Symptoms
As urinary free cortisol levels decreased, clinical 
improvements were evident at month 6 (see the 
Supplementary Appendix) and month 12 (Fig. 3). 
The mean changes from baseline to month 12 were 
as follows: systolic blood pressure, −6.1 mm Hg 
(95% CI, −9.8 to −2.4; P = 0.03); diastolic blood pres-
sure, −3.7 mm Hg (95% CI, −6.2 to −1.2; P = 0.03); 
triglycerides, –2 mg per deciliter (−0.2 mmol per 
liter) (95% CI, −27 to 0 mg per deciliter [−0.3 to 
0.0 mmol per liter]); LDL cholesterol, −15 mg per 
deciliter (−0.4 mmol per liter) (95% CI, −23 to 
−8 mg per deciliter [−0.6 to −0.2 mmol per liter]; 
P<0.001); weight, −6.7 kg (95% CI, −8.0 to −5.4; 
P<0.001); and health-related quality of life score, 
11.1 points (95% CI, 6.8 to 15.5). At months 6 and 
12, facial rubor and supraclavicular and dorsal 
fat pads were diminished in patients with avail-
able photographs (see the Supplementary Ap-
pendix).
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Figure 2. Mean Change in Urinary Free Cortisol Levels from Baseline 
to Month 12 and Proportion of Patients with Normalized Levels at Month 6.
Panel A shows the mean urinary free cortisol level at time points up to 
month 12 according to dose group; the change from baseline to months  
6 and 12 was significant for both the 600-μg group (P<0.001) and the 900-μg 
group (P<0.001). The dashed line represents the upper limit of the normal 
range (ULN), which is 145 nmol per 24 hours. The mean percentage change 
in the urinary free cortisol level from baseline to month 6 was –27.5% (95% 
CI, –55.9 to 0.9) in the 600-μg group and –48.4% (95% CI, –56.6 to –40.2) 
in the 900-μg group; the corresponding changes from baseline to month 12 
were –41.3% (95% CI, –66.0 to –16.6) and –54.5% (95% CI, –65.2 to –43.7). 
The median percentage change in the urinary free cortisol level was –47.9% 
(95% CI, –74.1 to –40.7) in the 600-μg group and –47.9% (95% CI, –66.9 to 
–35.5) in the 900-μg group at month 6 and –67.6% (95% CI, –72.7 to –42.4) 
and –62.4% (95% CI, –78.7 to –38.5), respectively, at month 12. I bars indi-
cate standard errors. Panel B shows the percentage of patients in whom the 
urinary free cortisol level was at or below the ULN at month 6, categorized 
according to whether hypercortisolism at baseline was mild (urinary free 
cortisol level, >1.5 to 2 times the ULN), moderate (>2 to 5 times the ULN), 
or severe or very severe (>5 times the ULN).
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Tumor Volume
Seventy-five patients (46%) had a measurable pitu-
itary tumor on MRI at baseline. At month 12, the 
mean percentage change in tumor volume was 
–9.1% (95% CI, –46.3 to 28.0) in the 600-µg 
group and –43.8% (95% CI, –68.4 to –19.2) in the 
900-µg group (see the Supplementary Appendix).
SAFETY
The safety profile of pasireotide in our study was 
similar to the safety profile of other somatostatin 
analogues with respect to adverse events such as 
gastrointestinal symptoms and gallstones, except 
that there was a higher frequency of hyperglycemia 
with pasireotide. Most drug-related adverse events 
were grade 1 or 2 and resolved without dose mod-
ification. The most frequently reported grade 3 or 
4 adverse events were hyperglycemia and diabetes 
mellitus, occurring in 13% and 7% of patients, 
respectively (Table 2). Overall, 118 of 162 patients 
(73%) had a hyperglycemia-related adverse event; 
6% of patients discontinued treatment because of 
a hyperglycemia-related adverse event. Preexisting 
diabetes or impaired glucose tolerance increased 
the risk of hyperglycemia-related adverse events.
Glucose and glycated hemoglobin levels in-
creased soon after initiation of treatment with pa-
sireotide but stabilized after initiation of glucose-
lowering therapy. The mean glycated hemoglobin 
level increased from 5.8% (in 78 patients) and 
5.8% (in 76 patients) in the 600-µg and 900-µg 
groups, respectively, at baseline to 7.2% (59 pa-
tients) and 7.4% (56 patients) at month 6 and to 
7.3% (40 patients) and 7.2% (38 patients) at month 
12 (see the Supplementary Appendix). At baseline, 
55 patients (34%) had diabetes and 39 (24%) had 
prediabetes (see the Supplementary Appendix for 
definitions). At study end, 51 (48%) of the 107 pa-
tients who did not have diabetes at baseline had 
a glycated hemoglobin level of 6.5% or more. No 
cases of diabetic ketoacidosis or hyperosmolar hy-
perglycemia were reported.
A new antidiabetic medication was initiated in 
74 of the 162 patients. In patients not receiving 
glucose-lowering medications at baseline, at least 
one medication was started during the study in 
53 of 129 patients (41%); 21 of 33 patients (64%) 
receiving antidiabetic medication at baseline re-
ceived at least one additional agent. Among pa-
tients in whom glucose-lowering therapy was initi-
ated during the study, the mean fasting plasma 
glucose level fell from 166.2 to 121.5 mg per 
deciliter (9.2 to 6.7 mmol per liter) in the 600-µg 
group and from 159.4 to 133.8 mg per deciliter 
(8.9 to 7.4 mmol per liter) in the 900-µg group.
Hypocortisolism-related adverse events (i.e., 
clinical symptoms consistent with adrenocorti-
cal insufficiency or glucocorticoid withdrawal) 
were reported in 13 patients (8%). In 11 of the 
patients, hypocortisolism resolved with a reduc-
tion in the pasireotide dose or temporary inter-
ruption of treatment, and subsequently, normal 
urinary free cortisol levels were maintained. Three 
patients (2%) had a newly occurring prolonga-
tion of the corrected QT interval (Fridericia’s for-
mula) of more than 480 msec. These events were 
sporadic, were evident on a single electrocardio-
gram, and did not require medical intervention or 
treatment interruption. No patients had a grade 2 
or higher arrhythmic disorder. Two patients had 
syncope, with no notable electrocardiographic 
changes. Mild (grade 1, or <3 times the upper 
limit of the normal range) transient elevations in 
liver enzyme levels were reported in 29% of pa-
tients, which in most cases returned to baseline 
levels with continued pasireotide therapy. No pa-
tient had aspartate aminotransferase or alanine 
aminotransferase levels that were more than 
3 times the upper limit of the normal range with 
a concomitant elevation of the bilirubin level. 
Of the 137 patients with a normal gallbladder on 
ultrasonographic examination at baseline, 9 had 
Figure 3 (facing page). Changes in Signs and Symptoms 
of Cushing’s Disease and Urinary Free Cortisol (UFC) 
Levels over Time in the Overall Study Population.
Panel A shows systolic blood pressure, Panel B diastolic 
blood pressure, Panel C triglycerides, Panel D low-density 
lipoprotein (LDL) cholesterol, Panel E body weight, and 
Panel F health-related quality-of-life (HRQoL) score. 
HRQoL was measured with the use of the CushingQoL 
questionnaire (in which scores range from 0 to 100, 
with higher scores indicating better quality of life). The 
numbers of patients included in analyses of mean UFC 
levels at various time points were as follows: 153 at base-
line, 144 at 1 month, 132 at 2 months, 131 at 3 months, 
123 at 4 months, 116 at 5 months, 111 at 6 months, 93 
at 9 months, and 77 at 12 months. The corresponding 
numbers of patients included in analyses of the mean 
values for signs, symptoms, and quality-of-life scores 
are shown beneath each graph. I bars indicate standard 
errors for both UFC level and clinical signs and symp-
toms. To convert the values for triglycerides to mg per 
deciliter, divide by 0.01129. To convert the values for 
LDL cholesterol to mg per deciliter, divide by 0.02586.
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detectable sludge and 27 had gallstones at the most 
recent assessment; 6 underwent cholecystectomy.
There were no deaths during treatment. Forty 
patients had serious adverse events, as defined in 
the Supplementary Appendix. Nine patients had 
a glucose-related serious adverse event (five had 
diabetes mellitus and four had hyperglycemia). 
Two patients had a serious adverse event related 
to hypocortisolism. One patient with a history of 
hypertension and uncontrolled hypothyroidism 
had a serious adverse event related to prolonga-
tion of the corrected QT interval (Bazett’s for-
mula). Four patients had cholelithiasis and un-
derwent intervention or hospitalization.
Discussion
This randomized, double-blind trial showed that 
50 of 103 patients had a substantial reduction (ei-
ther normalization or ≥50% reduction from base-
line) in the urinary free cortisol levels at month 6, 
including patients with very high baseline values. 
The majority of patients had moderate-to-severe 
hypercortisolism at baseline; the mean baseline 
level was approximately 6.5 times the upper limit 
of the normal range (78% of patients had a urinary 
free cortisol level that was more than 2 times the 
upper limit of the normal range). Normalization 
of urinary free cortisol was more likely to be 
Table 2. Most Frequently Reported Adverse Events (Occurring in ≥10% of Patients in Either Dose Group).*
Adverse Event
Pasireotide 600 µg  
Twice Daily 
(N = 82)
Pasireotide 900 µg  
Twice Daily 
(N = 80)
Overall 
(N = 162)
Grade 3 or 4 All Grades Grade 3 or 4 All Grades Grade 3 or 4 All Grades
number of patients (percent)
Diarrhea 3 (4) 48 (59) 2 (2) 46 (58) 5 (3) 94 (58)
Nausea 1 (1) 38 (46) 3 (4) 46 (58) 4 (2) 84 (52)
Hyperglycemia 8 (10) 31 (38) 13 (16) 34 (42) 21 (13) 65 (40)
Cholelithiasis 1 (1) 25 (30) 1 (1) 24 (30) 2 (1) 49 (30)
Headache 1 (1) 23 (28) 2 (2) 23 (29) 3 (2) 46 (28)
Abdominal pain 1 (1) 19 (23) 2 (2) 20 (25) 3 (2) 39 (24)
Fatigue 1 (1) 12 (15) 2 (2) 19 (24) 3 (2) 31 (19)
Diabetes mellitus 6 (7) 13 (16) 6 (8) 16 (20) 12 (7) 29 (18)
Nasopharyngitis 0 10 (12) 0 11 (14) 0 21 (13)
Alopecia 0 10 (12) 0 10 (12) 0 20 (12)
Asthenia 2 (2) 13 (16) 2 (2) 5 (6) 4 (2) 18 (11)
Glycated hemoglobin elevation 1 (1) 10 (12) 0 8 (10) 1 (1) 18 (11)
ALT elevation 1 (1) 11 (13) 3 (4) 6 (8) 4 (2) 17 (10)
GGT elevation 4 (5) 10 (12) 2 (2) 7 (9) 6 (4) 17 (10)
Peripheral edema 0 9 (11) 0 8 (10) 0 17 (10)
Upper abdominal pain 0 10 (12) 0 6 (8) 0 16 (10)
Decreased appetite 0 7 (9) 0 9 (11) 0 16 (10)
Hypercholesterolemia 0 7 (9) 0 9 (11) 0 16 (10)
Hypoglycemia 3 (4) 12 (15) 0 3 (4) 3 (2) 15 (9)
Type 2 diabetes mellitus 4 (5) 10 (12) 3 (4) 5 (6) 7 (4) 15 (9)
Anxiety 0 5 (6) 0 9 (11) 0 14 (9)
Influenza 0 9 (11) 0 5 (6) 0 14 (9)
Insomnia 0 3 (4) 0 11 (14) 0 14 (9)
Myalgia 1 (1) 10 (12) 0 4 (5) 1 (1) 14 (9)
* Adverse events were classified as grade 1 (mild), grade 2 (moderate), grade 3 (severe), or grade 4 (life-threatening or 
disabling). ALT denotes alanine aminotransferase, and GGT γ-glutamyltransferase.
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achieved in patients with lower baseline levels than 
in patients with higher baseline levels; however, pa-
sireotide also decreased the urinary free cortisol 
level in patients with severe hypercortisolism. Al-
though urinary free cortisol levels remained stable 
in selected patients whose dose of pasireotide was 
reduced, the results of this trial cannot be used to 
determine whether normal cortisol levels could 
have been achieved with a lower starting dose.
Urinary free cortisol levels decreased quickly, 
with a median reduction of approximately 50% by 
month 2, and remained stable in both groups, in-
dicating a continued therapeutic benefit. Patients 
unlikely to have a response to pasireotide may be 
identified within the first few months of treat-
ment; in our study, most patients (approximately 
90%) whose hypercortisolism was uncontrolled at 
months 1 and 2 continued to have uncontrolled 
hypercortisolism at months 6 and 12. Additional 
medical therapy in combination with pasireotide 
may be beneficial for patients in whom normal 
cortisol levels are not achieved. Cabergoline 
alone or in combination has shown efficacy in 
small studies,15-19 including a study in which pa-
sireotide was given alone or in combination with 
cabergoline with or without ketoconazole.19
The reduction in urinary free cortisol levels in 
response to pasireotide was accompanied by re-
ductions in serum cortisol and plasma corticotro-
pin levels, as well as improvements in signs and 
symptoms of Cushing’s disease. Body weight, sys-
tolic and diastolic blood pressure, and LDL choles-
terol levels were significantly reduced, and scores 
for health-related quality of life improved. Improve-
ments in signs and symptoms were not limited to 
patients in whom a normal urinary free cortisol 
level was achieved, suggesting that a reduction in 
the cortisol level may be associated with a long-
term clinical benefit. Additional studies are war-
ranted because concomitant medication changes 
were not monitored in our study, and there was no 
placebo group. A placebo-controlled trial of treat-
ment for Cushing’s disease was considered to 
be unethical, and there is no approved medical 
therapy, which precluded an active comparator 
group.
As with other somatostatin analogues, the most 
common adverse events were related to transient 
gastrointestinal discomfort. Hyperglycemia-related 
adverse events occurred in 73% of patients, and 6% 
of patients discontinued the study treatment be-
cause of such events. Glucose and glycated hemo-
globin levels increased soon after the initiation 
of treatment with pasireotide, necessitating the 
administration of medications to manage these 
complications. Preexisting diabetes or impaired 
glucose tolerance increased the risk of hyperglyce-
mia-related adverse events. In patients with Cush-
ing’s disease, alterations in insulin sensitivity that 
are associated with hypercortisolism often result 
in hyperglycemia, diabetes mellitus, or both. Data 
from studies involving healthy volunteers suggest 
that pasireotide-induced hyperglycemia is a result 
of decreased insulin and incretin secretion, where-
as insulin sensitivity is unaffected.20 In the current 
study, hyperglycemia occurred despite declining 
cortisol levels. Blood glucose should be monitored 
in pasireotide-treated patients, with special atten-
tion to patients with impaired glucose tolerance or 
diabetes mellitus. If blood glucose levels increase, 
appropriate treatment should be initiated promptly.
In conclusion, elevated cortisol levels in patients 
with Cushing’s disease were significantly reduced 
during treatment with pasireotide, a finding that 
supports the potential use of this agent as a pitu-
itary-specific treatment for Cushing’s disease.
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